Clinical trial
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With…
NCT00310830 · Actelion, Industry · Terminated
Key facts
| NCT number | NCT00310830 |
|---|---|
| Title | Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH) |
| Official title | Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease |
| Lead sponsor | Actelion, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Bosentan |
| Enrollment | 14 |
| Start date | Mar 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Apr 5, 2006 |
| Last update posted | Feb 4, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: